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and their combination are medicines of choice for treatment of
glaucoma in Russia. CONCLUSIONS: More attention is being
payed to prostaglandins and CAIs. The information of ophthal-
mologist and their patients about the cost of therapy is a very
important component for pharmacoeconomical decisions
together with medical effectiveness of treatment. But it is rather
low in Russia in whole.
EYE/EAR/SKIN DISEASES/DISORDERS
EYE/EAR/SKIN DISEASES/DISORDERS—Quality of
Life/Utility/Preference Studies
PES14
RESPONSIVENESS OF SELF-REPORTED VISUAL
FUNCTIONING IN AGE-RELATED MACULAR DEGENERATION
(AMD) PATIENTS TO GENERAL HEALTH AND CHANGES IN
VISUAL ACUITY IN A PHASE I/II RANDOMIZED CONTROLLED
TRIAL OF LUCENTISTM (RANIBIZUMAB; RHUFAB V2)
Globe D1,Tonnu IQ1, Chang TS1, Fine J2
1University of Southern California, Los Angeles, CA, USA;
2Genentech, Inc, South San Francisco, CA, USA
OBJECTIVES: Evaluate association of National Eye Institute
Visual Functioning Questionnaire-25 (VFQ-25) score changes
with systemic comorbidities and visual acuity (VA) changes in
neovascular AMD patients in a phase I/II randomized controlled
trial of LucentisTM (ranibizumab; rhuFab V2). METHODS: At
baseline and three months, 57 patients completed the VFQ-25
(self-reported visual function) and VA was measured. The pres-
ence of seven comorbidities was recorded at baseline. VA score
(number of lines read) was converted to a weighted log of the
minimum angle of resolution (0.25 worse eye logMAR + 0.75
better eye logMAR). To estimate the relative association of
changes in VA and comorbidities with changes in VFQ-25 scores,
separate regression models of three-month changes in each sub-
scale score on the logMAR scores were developed for each
comorbidity. RESULTS: Mean number of comorbidities was 3,
including: 25 (44%) hypertension, 24 (42%) arthritis, 14 (25%)
hearing loss, 12 (21%) diabetes, 12 (21%) psychiatric disease,
12 (21%) back pain, 11 (19%) cancer. Due to small sample size,
only VA estimates in the regression were signiﬁcant after con-
trolling, individually, for the comorbidities. For all models, a
one-line (0.1 logMAR) worsening in VA was signiﬁcantly asso-
ciated with decreased subscale scores, particularly those related
to central vision (Near Activities, Distance Activities). VA alone
explained 11% of the variation in the VFQ-25 change between
baseline and 3 months in the Near Activities subscale. Inclusion
of an individual comorbidity improved the explanatory power
of the models slightly (r2): to 12% for hypertension, hearing loss,
diabetes, psychiatric disease, cancer, and back pain, 13% for
arthritis subjects, and 14% when summing all comorbidites a
patient had. CONCLUSIONS: Some selected VFQ-25 subscale
scores were decreased with the presence of visual impairment
and comorbidities. Systemic diseases should be included in VFQ-
25 assessments to control for differences between patients and
samples.
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IMPACT OF ATOPIC DERMATITIS ON PARENT&PSI;S QUALITY
OF LIFE AND USE OF DIRECT RESOURCES IN PATIENTS
BETWEEN 2 AND 12 YEARS OLD. DAES STUDY
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OBJECTIVES: Assess the impact of atopic dermatitis (AD) on
parent’s quality of life (QoL) and use of health direct resources
in patients between 2 and 12 years old. METHODS: An obser-
vational burden-disease study of nine months of follow-up in
which AD patients 2 to 12 years old were included according to
Haniﬁn&Rajka diagnostic criteria. Four visits were conducted
per protocol (baseline, 3, 6, 9 months). Disease severity was
assessed by Investigator’s Global Assessment(IGA). Parents’ QoL
was assessed by Parents Index of Quality of Life Atopic Der-
matitis (PiQoL-AD) and by Visual Analogue Scale(VAS) of the
EQ-5D questionnaire. Use of direct resources in the last three
months were assessed retrospectively by medical ﬁles data or
direct interviews to patients’ parents. RESULTS: Results are
referred to baseline visit. A total of 240 children with AD were
included in the analysis, with mean age (SD) 5.3 (2.7), 52% were
boys. The most frequent careers were mothers (87.8%), 36.24
(4.9) years older (mean(SD)). 19.18% of patients had clear or
almost clear AD (IGA < 2), 31.25% had mild disease (IGA = 2),
37.91% had moderate disease (IGA = 3) and 11.68% had severe
or very severe disease (IGA = 4 or IGA = 5). Disease severity had
a signiﬁcant impact on parent’s QoL: mean scores of PIQoL-AD
questionnaire increased 4.9 points and VAS score decrease 16.28
points (p < 0.5), indicating a worsening health state. In the last
3 months, 79.69% of patients required medical assistance,
mainly from paediatricians or dermatologists; 81.84% pharma-
cological treatment and 24.11% laboratory tests, 17.61%
unscheduled visits and 12.73% went to the Emergency Depart-
ment. Use of direct resources increased with severity (p < 0.5).
CONCLUSIONS: Parents’ QoL tends to reduce progressively
from mild AD states while resource utilization increases pro-
gressively. Proper management of AD may help maintain patients
in less severe disease states, reducing the negative impact on
quality of life and on resource utilization.
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SCALING PROPERTIES OF THE DERMATOLOGY LIFE
QUALITY INDEX (DLQI)
McKenna SP, Meads DM, Doward LC
Galen Research, Manchester, UK
OBJECTIVES: The Dermatology Life Quality Index (DLQI) is a
widely-used HRQL measure. The instrument is intended for use
by patients with any skin disease. The aim of this study was to
assess the scaling properties of the DLQI and whether it is free
from differential item functioning (DIF). METHODS: DLQI
data collected in atopic dermatitis (AD) and psoriasis studies in
the UK were subjected to Rasch (one-parameter logistic item
response theory) analysis. Fit to the Rasch model was examined
via Chi2 statistics and assessments of DIF related to gender, age
and type of skin disease were made. RESULTS: Sample: Psoria-
sis study: n = 148 (49.7% male; mean age 45.1 +/- 14.9; mean
illness duration 20.9 +/- 13.5; mean DLQI score 8.7 +/- 6.7);
AD study: n = 286 (29.4% male; mean age 44.9 +/- 16.4; mean
illness duration 29.0 +/- 16.7; mean DLQI score 7.0 (+/-5.1).
The DLQI showed signiﬁcant misﬁt to the Rasch model in pso-
riasis and AD—indicating that the instrument is not unidimen-
sional. Several DLQI items exhibited DIF by age and gender.
Four of the ten items in the measure exhibited DIF by disease.
CONCLUSIONS: The DLQI was found to misﬁt the Rasch
model in both patient samples, indicating that it is unsafe to use
the total score on the measure. Its validity is further compro-
mised by DIF associated with age and gender which indicates
that items work differently with different subgroups of patients.
For example, the item “How much has your skin inﬂuenced the
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clothes you wear?” exhibited DIF by gender in both psoriasis
and AD samples, indicating that women were signiﬁcantly more
likely than men (at the same level of QoL) to afﬁrm the item.
Finally, the extensive DIF by disease observed indicates that it is
not valid to compare the scores of AD and psoriasis patients
using this measure.
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LIVING WITH A DERMATOSIS: A NATIONAL SURVEY OF
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OBJECTIVES: To assess the consequences of dermatological dis-
eases on the quality of life of the patients. METHODS: Every
Belgian Dermatologist received a sample of 30 questionnaires
including the DLQI and the SF-12 that they distributed during
the “National Week of Dermatology” to the ﬁrst 30 patients
coming to the consulting room. The SF-12 is a generic measure
of health status, composed of two dimensions, a Physical one
(PCS-12) and a Mental one (MCS-12). The lower the score, the
more the quality of life is affected. The DLQI is a questionnaire
designed to measure and compare disability in different skin con-
ditions. The higher the score, the more the quality of life is
affected. RESULTS: The male/female ratio was 37%/63% and
the mean age was 46.76 years. Concerning the patients ‘state of
health, MCS-12 and PCS-12 were respectively 43.8 (SD = 11.3)
and 48.1 (SD = 9.4); with a signiﬁcant difference in the mental
dimension between Flemish (46.4, SD = 10.6) and Walloons
(40.7, SD = 11.3) (p = 0.0001). The quality of life score, assessed
by the DLQI, shows a quality of life’s impairment with a score
of 6.1 (SD = 5.9). CONCLUSIONS: Our population reﬂect a
QoL impairment comparable to the ranges obtained when ini-
tially validating the DLQI; i.e. for patients suffering psoriasis the
DLQI mean score was 8.9, it was 4.3 for patients suffering from
acne, and 6.7 for patients with viral warts. Concerning patients’
health status we observe for every patient, whatever his skin
disease was, an important impairment in the mental dimension
of the SF-12 compared to a standard population and a slight one
for the physical dimension (except for patients with acne who
are younger, mean age = 28 years old).
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INTERPRETATION OF SCORES ON THE PSORIASIS INDEX OF
QOL (PSORIQOL)
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OBJECTIVES: The Psoriasis Index of Quality of Life
(PSORIQoL) is a 25-item quality of life (QoL) scale speciﬁc to
psoriasis. It has been shown to have excellent scaling properties
and to be reproducible and valid. The aim of the present study
was to assess the responsiveness of the PSORIQoL and provide
data that will aid in the interpretation of scores on the measure.
METHODS: Data from a 13-week, placebo-controlled clinical
trial in psoriasis were analysed. PSORIQoL responsiveness was
assessed using Effect Size (ES), Standardised Response Mean
(SRM) and the Responsiveness Statistic (RS). The Standard Error
of Measurement (SEM), a distribution-based method of inter-
preting scores was also calculated. An anchor-based Minimal
Important Difference (MID; which provides an assessment of
clinical meaningfulness) was derived by measuring QoL change
accompanying changes in disease severity on a six-point Investi-
gator’s Global Assessment (IGA). The IGA ranges from zero
(clear) to ﬁve (very severe disease). RESULTS: A total of 69 pso-
riasis patients completed the PSORIQoL (51/ 74% male; mean
age 43.8 +/- 11.7; baseline mean PSORIQoL = 12.2 +/- 6.4; 13-
week PSORIQoL = 9.8 +/- 7.1). Effect Sizes ranged from 0.37
for the placebo arm to 0.67 for the most potent treatment arm.
Changes for the whole sample were signiﬁcant over time (p =
.007), with SRM = 0.40 and RS = 0.51. According to ES, changes
of 1.3, 3.2, and 5.1 represent small, moderate and large changes
in PSORIQoL scores respectively. One SEM = 1.91; 1.96 SEM
= 3.75. A move from Severe to Moderate and from Moderate to
Mild disease on the IGA requires a change of 1.8 and 2.7 points,
respectively in PSORIQoL scores. CONCLUSIONS: The
PSORIQoL was shown to be responsive to treatment effects. The
MID for the measure is between two and three points.
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SENSITIVE SKIN: QUALITY OF LIFE IMPACT
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OBJECTIVES: To evaluate the prevalence of “sensitive skin”
among a representative sample of the French population.
METHODS: We questioned a representative sample of the entire
French population aged 15 years and above. The SF-12 is a
generic measure of health status. The SF-12 is composed of two
dimensions, a Physical Component Summary (PCS-12) and a
Mental Component Summary (MCS-12). The results are stan-
dardised on the general US population [mean score of 50 (SD =
10)], so results can be meaningfully compared to an average and
compared one another. The lower the score, the more the quality
of life is affected. The SF-12 was intended for parents in order
to assess their own quality of life. RESULTS: Out of the French
population aged over 15 years, 51.9% felt that they had sensi-
tive or very sensitive skin. An evaluation of the quality of life,
using SF-12, revealed a change in the mental dimension of the
score for subjects of both sexes, “very sensitive or sensitive”
compared with “slightly or not sensitive”: Men: 45.61 versus
49.70 (p < 0.0001), Women: 44.68 versus 47.30 (p = 0.0024).
In addition, comparisons of the various degrees of sensitivity
revealed signiﬁcant differences for both men (very sensitive:
43.57, sensitive: 46.12, slightly: 48.43, not sensitive: 51.34) and
women (very sensitive: 42.21, sensitive: 45.54, slightly: 46.99,
not sensitive: 47.84), showing that the alteration in the mental
dimension was more severe when the skin was more sensitive.
CONCLUSIONS: As measured by SF-12, the mental dimension
of their quality of life was affected.
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SUNBURNS AND QUALITY OF LIFE
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OBJECTIVES: The ICARE programme’s objective is to asses
patients’ knowledge of the consequences of sun exposure. Its
speciﬁcity and relevance are based on the fact that patients will
be asked to ﬁll in the questionnaire after a sunburn. METHODS:
Every patient coming to an outpatient pharmacy in order to
obtain an advice or treatment following a sunburn was remitted
a questionnaire assessing the consequences of sun exposure. The
Dermatology Life Quality Index (DLQI) is a validated question-
naire to measure and compare disability in different skin condi-
tions. RESULTS: First results showed evidence of a QoL
